Positive new safety data for AstraZeneca’s Movantik
Furtheranalysis of the Phase III KODIAC-04, KODIAC-05 and KODIAC-08 studies were presented Saturday at Digestive Disease Week (DDW) 2015 in Washington DC, USA, showed that AstraZeneca’s (LSE: AZN) Movantik (naloxegol) had a similar incidence of adverse events (AEs) among elderly patients as compared to placebo or usual care.
The study evaluated the effects of daily oral administration of Movantik 12.5mg or 25mg versus placebo among outpatients 65 years and older with opioid-induced constipation (OIC) and chronic non-cancer pain.
The incidence of AEs reported among patients taking Movantik was similar to those taking placebo or usual care.Safety results among this subset were generally consistent with those seen in the overall patient populations from Phase III studies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze